ArticlePloS one2013
The opportunistic pathogen Propionibacterium acnes: insights into typing, human disease, clonal diversification and CAMP factor evolution.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03450369 (A Phase 1B Dose Escalating Study of the Safety, Short-Term Engraftment and Action of a Singly-Applied NB01 in Adults With Moderate Acne), which is not on this map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1B Dose Escalating Study of the Safety, Short-Term Engraftment and Action of a Singly-Applied NB01 in Adults With Moderate Acne
Who cites it
72 citing papers in PubMed, 140 citations in OpenAlex.
- Whole Genome Sequencing Reveals Antibiotic Resistance Heterogeneity and Metabolic Signatures of Cutibacterium acnes in Atopic Dermatitis.Current microbiology · 2026Article
- The Bacterial Landscape of Facial Skin: From Homeostasis to Skin Conditions.Dermatology and therapy · 2026Review
- Skin Microbiome in Health and Disease: Dysbiosis and the Emerging Role of Biotics in Therapy and Protection.International journal of molecular sciences · 2026Review
- Characterization ofFrontiers in surgery · 2026Article
- Review
- Unique genetic diversity of Propionibacterium acnes isolated from human facial skins in Thailand revealed by the multi-locus sequence typing scheme.BMC microbiology · 2025Article
- Synergistic Antimicrobial Activity of Vancomycin, Ceftriaxone, and Gentamicin AgainstAntibiotics (Basel, Switzerland) · 2025Article
- The Role ofInternational journal of molecular sciences · 2025Review
- Distinct Intraspecies Variation ofMicroorganisms · 2025Article
- Decoding Acne Vulgaris: Insights into Pathogenesis, Treatment Modalities, Diagnosis and Recent Advancements.Recent advances in inflammation & allergy drug discovery · 2025Review
- Increased biofilm formation in dual-strain compared to single-strain communities of Cutibacterium acnes.Scientific reports · 2024Article
- Facemask acne attenuation through modulation of indirect microbiome interactions.NPJ biofilms and microbiomes · 2024Article
- DistinctFrontiers in microbiomes · 2024Article
- Comparative Genomic Analysis ofMicroorganisms · 2023Article
- Phenotypic and Genotypic Characterization ofMicroorganisms · 2023Article
- New insights into the role of Cutibacterium acnes-derived extracellular vesicles in inflammatory skin disorders.Scientific reports · 2023Article
- Shotgun sequencing of sonication fluid for the diagnosis of orthopaedic implant-associated infections withFrontiers in cellular and infection microbiology · 2023Article
- Skin dysbiosis and Cutibacterium acnes biofilm in inflammatory acne lesions of adolescents.Scientific reports · 2022Article
- Microbiological Characterization ofAntibiotics (Basel, Switzerland) · 2022Article
- Interference and co-existence of staphylococci and Cutibacterium acnes within the healthy human skin microbiome.Communications biology · 2022Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
We previously described a Multilocus Sequence Typing (MLST) scheme based on eight genes that facilitates population genetic and evolutionary analysis of P. acnes. While MLST is a portable method for unambiguous typing of bacteria, it is expensive and labour intensive. Against this background, we now describe a refined version of this scheme based on two housekeeping (aroE; guaA) and two putative virulence (tly; camp2) genes (MLST4) that correctly predicted the phylogroup (IA1, IA2, IB, IC, II, III), clonal complex (CC) and sequence type (ST) (novel or described) status for 91% isolates (n = 372) via cross-referencing of the four gene allelic profiles to the full eight gene versions available in the MLST database (http://pubmlst.org/pacnes/). Even in the small number of cases where specific STs were not completely resolved, the MLST4 method still correctly determined phylogroup and CC membership. Examination of nucleotide changes within all the MLST loci provides evidence that point mutations generate new alleles approximately 1.5 times as frequently as recombination; although the latter still plays an important role in the bacterium's evolution. The secreted/cell-associated 'virulence' factors tly and camp2 show no clear evidence of episodic or pervasive positive selection and have diversified at a rate similar to housekeeping loci. The co-evolution of these genes with the core genome might also indicate a role in commensal/normal existence constraining their diversity and preventing their loss from the P. acnes population. The possibility that members of the expanded CAMP factor protein family, including camp2, may have been lost from other propionibacteria, but not P. acnes, would further argue for a possible role in niche/host adaption leading to their retention within the genome. These evolutionary insights may prove important for discussions surrounding camp2 as an immunotherapy target for acne, and the effect such treatments may have on commensal lineages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.